AI Multi-Omics Analytics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 1.2 billion
Estimated Base Value
2035 Forecast
US$ 7.7 billion
Projected Market Value
CAGR 2026–2035
20.4%
Compound Annual Growth
Largest Segment
AI-powered Multi-Omics Software Platforms
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
Asia Pacific
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
Insilico Medicine
Emerging Players
Isomorphic Labs, Xaira Therapeutics
AI Multi-Omics Analytics Market Overview
The AI Multi-Omics Analytics Market in pharmaceuticals applies artificial intelligence and machine learning to integrate, analyze, and interpret complex data from genomics, proteomics, metabolomics, and transcriptomics. This market serves pharmaceutical and biotechnology companies, and contract research organizations. Its purpose is to accelerate drug discovery, identify biomarkers, understand disease mechanisms, and advance precision medicine. Solutions enhance R&D efficiency by providing predictive insights, facilitating target validation, and optimizing therapeutic development strategies, leveraging AI to unlock the synergistic potential of diverse biological data for pharmaceutical innovation.
The market is estimated at $1.2 Bn in 2025 and is forecast to reach $7.7 Bn in 2035, growing at a CAGR of 20.4% (2025-2035). Demand is driven by the explosive growth in multi-omics data generation and the urgent need for accelerated drug discovery processes, alongside advancements in AI and machine learning. However, challenges in integrating diverse multi-omics datasets, navigating complex regulatory pathways, and the substantial cost of AI model development and deployment act as restraints.
The market is segmented by Type (AI-Powered Multi-Omics Software Platforms, AI-Driven Multi-Omics Analytics Services, AI-Enabled Multi-Omics Data Integration Tools, AI-Based Predictive Modeling & Simulation Tools, AI-Enhanced Biomarker Discovery Solutions, AI Multi-Omics Database & Knowledgebases, AI Multi-Omics Clinical Decision Support Tools, AI Multi-Omics Research & Development Solutions), Application, Technology, End-User, Component, and Deployment. It is served across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Leading companies include Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, SOPHiA GENETICS, Tempus, Insitro, Valo Health, OWKIN, Ginkgo Bioworks, Relay Therapeutics, and Deep Genomics. The full report covers global market analysis, focusing on pharmaceutical and biotechnology end-users, and applications specific to drug discovery and development from 2025 to 2035.
Market Definition & Overview
The AI Multi-Omics Analytics Market in pharmaceuticals involves the application of artificial intelligence and machine learning algorithms to integrate, analyze, and interpret complex data sets derived from multiple omics layers, including genomics, proteomics, metabolomics, and transcriptomics. This market primarily serves pharmaceutical and biotechnology companies, and contract research organizations, aiming to accelerate drug discovery, identify novel biomarkers, understand disease mechanisms, and advance precision medicine. Solutions within this market enhance the efficiency of R&D pipelines by providing predictive insights, facilitating target validation, and optimizing therapeutic development strategies. It focuses on leveraging AI to unlock the synergistic potential of diverse biological data for pharmaceutical innovation.
Scope
- Global market analysis covering major geographic regions
- Focus on pharmaceutical and biotechnology end-users
- Applications specific to drug discovery and development
- Analysis period spanning from 2025 to 2035
Inclusions
- AI-powered platforms for multi-omics data integration and analysis
- Software solutions for drug target identification and validation
- Predictive analytics tools for disease progression and treatment response
- AI-driven services for biomarker discovery and therapeutic development
- Cloud-based AI multi-omics analytics solutions
- Tools for multi-omics data visualization and interpretation
Exclusions
- Standalone single-omics analytics platforms without AI integration
- AI solutions for clinical diagnostics outside pharmaceutical R&D
- Hardware for omics data generation like sequencers
- Conventional statistical analysis tools lacking AI capabilities
- AI applications in non-pharmaceutical industry sectors
Market Size Forecast
Executive Summary
• The AI Multi-Omics Analytics market is valued at $1.2 Bn in 2025 and is forecast to reach $7.7 Bn by 2035, reflecting a robust CAGR of 20.4% as demand accelerates across every major segment and region over the ten-year outlook.
• AI-powered Multi-Omics Software Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• The competitive landscape is witnessing rapid consolidation and strategic partnerships, driven by the need for integrated multi-omics platforms and end-to-end AI analytical capabilities across the pharmaceutical value chain.
• Accelerating adoption crucially hinges on demonstrating clear ROI through precision medicine advancements and biomarker discovery, thereby propelling global pharmaceutical R&D efficiency and drug development.
• The convergence of advanced AI, machine learning algorithms, and robust multi-omics data integration is fundamentally redefining drug discovery pipelines and accelerating personalized therapeutics development globally.
• Evolving global regulatory frameworks for AI-driven diagnostics and drug development necessitate proactive industry engagement to foster innovation while ensuring data privacy and ethical standards.
• Emerging markets represent significant untapped growth potential, demanding localized data strategies and tailored AI solutions to address their diverse genomic and healthcare needs effectively.
• Substantial venture capital inflows are targeting specialized AI multi-omics startups offering niche analytical tools, indicating a fragmented yet innovation-rich investment landscape poised for future breakthroughs.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The AI Multi-Omics Analytics market is currently valued at $1.2 billion in the base year.
Future Market Projection
This market is projected to reach $7.7 billion by the forecast year, indicating significant expansion.
Strong Growth Rate
The market is set for impressive growth, with a Compound Annual Growth Rate (CAGR) of 20.4% from the base year to the forecast year.
Overall Market Expansion
The AI Multi-Omics Analytics market is poised for robust expansion, growing from $1.2 billion in the base year to $7.7 billion by the forecast year at a CAGR of 20.4%.
Drug Discovery Lead
The drug discovery segment is anticipated to be a leading area within this market, leveraging AI for identifying new therapeutic targets and accelerating development.
Personalized Medicine Focus
A notable trend driving market growth is the increasing application of AI Multi-Omics Analytics to advance personalized medicine through integrated biological data analysis for tailored treatments.
Market Dynamics
Market Trends
- Growing integration of diverse omics datasets for holistic insights.
- Accelerated adoption of AI for precision medicine applications.
- Cloud-based AI platforms are becoming standard for multi-omics analysis.
- Emphasis on explainable AI (XAI) for transparent drug discovery.
Growth Drivers
- Explosive growth in multi-omics data generation fuels AI demand.
- Urgent need for accelerated and efficient drug discovery processes.
- Increasing demand for personalized and targeted therapeutics.
- Significant advancements in AI and machine learning algorithms.
Restraints
- Integrating diverse multi-omics datasets presents significant technical challenges.
- Navigating complex regulatory pathways for AI solutions remains a major hurdle.
- The substantial cost of AI model development and deployment limits adoption.
- A scarcity of experts in both AI and omics hinders market growth.
Opportunities
- Development of advanced AI models for complex disease understanding.
- Expansion into integrating multi-omics with real-world clinical data.
- AI-powered prediction of drug efficacy and potential adverse effects.
- Collaborations between AI and pharmaceutical companies for innovation.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI-Powered Multi-Omics Software PlatformsAI-Driven Multi-Omics Analytics ServicesAI-Enabled Multi-Omics Data Integration ToolsAI-Based Predictive Modeling & Simulation ToolsAI-Enhanced Biomarker Discovery SolutionsAI Multi-Omics Database & KnowledgebasesAI Multi-Omics Clinical Decision Support ToolsAI Multi-Omics Research & Development Solutions |
| By Application | Drug Discovery & DevelopmentPrecision MedicineBiomarker Discovery & ValidationTarget Identification & ValidationDisease Prognosis & DiagnosisClinical Trials OptimizationPharmacogenomicsToxicology & Safety Assessment |
| By Technology | Machine LearningDeep LearningNatural Language ProcessingComputer VisionReinforcement LearningGenerative AIExplainable AIPredictive Analytics Algorithms |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesContract Research OrganizationsAcademic & Research InstitutionsHospitals & ClinicsDiagnostic Laboratories |
| By Component | AI & Machine Learning ModulesOmics Data Processing ModulesData Integration & Harmonization ToolsVisualization & Reporting InterfacesDatabase Management SystemsSecurity & Compliance ModulesApplication Programming Interfaces |
| By Deployment | Cloud-BasedOn-PremiseHybrid |
Regional Analysis
- North America dominates the AI Multi-Omics Analytics market, driven by substantial R&D investments and a high concentration of leading pharmaceutical and biotech companies. Its advanced healthcare infrastructure and early AI adoption in drug discovery further establish its strong market leadership.
- Asia-Pacific is emerging as the fastest-growing region in AI Multi-Omics Analytics, propelled by increasing healthcare investments and a growing focus on precision medicine. Rising chronic disease prevalence and government support for biotech R&D in countries like China significantly drive this expansion.
- Europe presents a noteworthy trend focusing on ethical AI integration within multi-omics research for precision medicine. Strong collaborative initiatives between academia and industry are key. Robust data privacy regulations shape its unique, responsible adoption of AI Multi-Omics Analytics.
| Asia PacificXX.X% | North AmericaXX.X% | EuropeXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Dominates in advanced research and development, backed by robust funding, a concentration of leading biopharmaceutical companies, and a strong regulatory framework supporting innovation.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiencing growth due to rising healthcare expenditure, increasing investment in biotech startups, and a growing recognition of AI's potential to address unique public health challenges in the region.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Benefits from strong academic-industry collaborations, significant public and private funding for life sciences, and a growing focus on personalized medicine initiatives across the EU and UK.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Driven by significant government investment in R&D, a large patient pool, and rapid adoption of digital health technologies, particularly in countries like China, Japan, and India.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Showing nascent growth driven by strategic investments in health technology and genomics research in GCC countries, alongside humanitarian initiatives leveraging AI for health outcomes in parts of Africa.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads with massive R&D investment, a robust pharmaceutical and biotech sector, and extensive adoption of AI in drug discovery and precision medicine, driving innovation in multi-omics analytics. Its strong academic-industrial collaborations and venture capital funding further accelerate advancements in this specialized field. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | Brazil, as the largest economy in Latin America, has a significant pharmaceutical market and growing investments in biotechnology research. Its focus on public health and genomics initiatives is creating demand for multi-omics analytics. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany benefits from a strong pharmaceutical industry, leading life science research institutes, and significant government funding for AI and health tech. Its focus on personalized medicine and advanced bioinformatics drives the adoption of multi-omics analytics. |
| 4 | China | US$ XX.X Mn | XX.X% | China is rapidly expanding its pharmaceutical R&D capabilities, with massive government investment in AI, genomics, and biotechnology. Its large population and focus on precision medicine are driving significant demand for multi-omics analytics. |
| 5 | Israel | US$ XX.X Mn | XX.X% | Israel is a global leader in high-tech and biotech innovation, with a vibrant startup ecosystem and significant venture capital investment in AI in healthcare. Its advanced research institutions and focus on precision medicine drive demand for multi-omics analytics. |
Countries Covered (29)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Netherlands, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Taiwan, Australia, Singapore, Malaysia, Rest of Asia Pacific, Israel, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Insilico Medicine | XX.X% | Utilize generative AI to discover novel targets and design de novo molecules for drug discovery, accelerating the process from target identification to clinical trials. | — | — | Pharma.AI platformChemistry42Biology42+1 |
| 2 | BenevolentAI | XX.X% | Leverage a proprietary AI platform to identify new drug targets, understand disease mechanisms, and advance drug candidates across various therapeutic areas. | — | — | Benevolent PlatformBenevolentAI Drug Discovery PipelineAI-enabled Drug Discovery Partnerships |
| 3 | Recursion Pharmaceuticals | XX.X% | Integrate automated wet-lab experimentation with a vast biological and chemical dataset and machine learning to systematically map human biology and discover new therapeutics. | — | — | Recursion OSPhenomapsTarget ID Platform+1 |
| 4 | Exscientia | XX.X% | Apply proprietary AI algorithms to automate drug design and optimize drug development, aiming to create better medicines faster and more efficiently. | — | — | AI-driven Drug Discovery PlatformExscientia PipelinePatient-First AI |
| 5 | SOPHiA GENETICS | XX.X% | Provide an AI-driven multimodal data analytics platform to integrate genomic and real-world clinical data, assisting healthcare professionals in making data-driven diagnoses and treatment decisions. | — | — | SOPHiA DDM PlatformAI-driven applications for OncologyRare Diseases+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, SOPHiA GENETICS, Tempus, Insitro, Valo Health, OWKIN, Ginkgo Bioworks, Relay Therapeutics, Deep Genomics, Terray Therapeutics, Schrödinger, ConcertAI, Immunai, Eagle Genomics, DNAnexus, LabGenius, PostEra
The global AI Multi-Omics Analytics market features a competitive landscape led by Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, SOPHiA GENETICS, and Tempus, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Insilico Medicine
BenevolentAI
Recursion Pharmaceuticals
Exscientia
SOPHiA GENETICS
Tempus
Insitro
Valo Health
OWKIN
Ginkgo Bioworks
Relay Therapeutics
Deep Genomics
Terray Therapeutics
Schrödinger
ConcertAI
Immunai
Eagle Genomics
DNAnexus
LabGenius
PostEra
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
DeepOmics AI Unveils Next-Gen Multi-Omics Integration Platform
DeepOmics AI announced the launch of its new 'IntegratoX' platform, designed to seamlessly integrate diverse multi-omic datasets with advanced machine learning for enhanced drug target identification and biomarker discovery. This aims to significantly accelerate preclinical drug development.
PharmaGiant Inc. Acquires AI Multi-Omics Innovator BioInsight Analytics
Global pharmaceutical leader PharmaGiant Inc. has acquired BioInsight Analytics, a pioneering startup specializing in AI-driven multi-omics data interpretation. The acquisition aims to integrate BioInsight's advanced predictive analytics into PharmaGiant's drug discovery pipeline, strengthening its precision medicine initiatives.
NIH Forms Strategic Alliance with OmicsAI for Cancer Research
The National Institutes of Health (NIH) has announced a major strategic partnership with OmicsAI, a prominent AI multi-omics analytics firm, to develop new computational tools for understanding complex cancer pathways. This collaboration seeks to leverage OmicsAI's expertise to uncover novel therapeutic targets and accelerate personalized oncology treatments.
BioVenture Capital Leads US$ XX.X Series B for GenomixAI
GenomixAI, a rapidly growing startup focused on AI-powered multi-omics for rare disease diagnostics, secured US$ XX.X in Series B funding led by BioVenture Capital. The investment will fuel the expansion of GenomixAI's platform capabilities and accelerate its market penetration in clinical diagnostics and drug repurposing.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $1.2 Bn |
| Market Size (Forecast) | $7.7 Bn |
| CAGR | 20.4% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 29 Countries |
| Segments Covered | 6 Segments, 40 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the AI Multi-Omics Analytics Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The AI Multi-Omics Analytics market is estimated at $1.2 Bn in 2025. It is forecast to reach $7.7 Bn in 2035, indicating substantial growth over the forecast period.
The AI Multi-Omics Analytics market is forecast to grow at a CAGR of 20.4% between 2025 and 2035. This growth reflects increasing adoption of AI in pharmaceutical R&D.
The main segments include Type (e.g., AI-Powered Multi-Omics Software Platforms), Application (e.g., Drug Discovery & Development), Technology (e.g., Machine Learning), End-User (e.g., Pharmaceutical Companies), Component, and Deployment. These categories define the scope of solutions and services offered.
Leading companies in this market include Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, SOPHiA GENETICS, Tempus, Insitro, Valo Health, OWKIN, Ginkgo Bioworks, Relay Therapeutics, and Deep Genomics. These firms are key players in developing AI-driven multi-omics solutions.
The report provides a global market analysis, focusing on pharmaceutical and biotechnology end-users. It covers applications specific to drug discovery and development, with an analysis period from 2025 to 2035. It includes AI-powered platforms, software, and services for multi-omics data integration and analysis.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
AI Clinical Trial Analytics Market
$1.0 Bn in 2025 · 21.5% CAGR
Clinical Trial Analytics Market
$1.5 Bn in 2025 · 13.0% CAGR
Life Science Analytics Market
$14.6 Bn in 2025 · 21.5% CAGR
Pharmaceutical Quality Analytics Market
$2.9 Bn in 2025 · 12.4% CAGR
Biological Process Analytics Market
$4.4 Bn in 2025 · 5.9% CAGR
Biopharma Manufacturing Analytics Market
$2.1 Bn in 2025 · 19.2% CAGR
Bioprocess Analytics Market
$2.0 Bn in 2025 · 15.6% CAGR
Digital Omics Platform Market
$4.9 Bn in 2025 · 15.1% CAGR